Evaluation of bone health in breast cancer patients with germline pathogenic variants

Patients with breast cancer (BC) have an increased risk of bone loss due to both the cancer itself and the side effects of antineoplastic therapies. This study evaluated the bone health of survivors of BC with germline pathogenic variants (PVs). This is a retrospective cross-sectional study. We identified 165 BC patients in whom PVs in BC susceptibility genes were diagnosed between February 2017 and December 2022 at our breast health center in Acibadem Altunizade Hospital. Only 80 patients underwent dual-energy X-ray absorptiometry (DXA) at the time of diagnosis. The median patient age was 44 years. Of 80 patients, 47% had (n = 38) had BRCA1 and BRCA2, while the remaining 53% (n = 42) had other PVs, which we refer to as non-BRCA. Risk-reducing bilateral salpingo-oophorectomy (RRBSO) was performed in 21 patients with BRCA and 6 patients with non-BRCA PVs patients (p < 0.001). At the 68-months follow up period, a total of 53% had osteopenia, and 11% had osteoporosis. According to the mutation type, among patients with BRCA1 and BRCA2, 47% exhibited osteopenia and 11% had osteoporosis. In non-BRCA, 57% had osteopenia and 12% had osteoporosis (p > 0.05). In this study, we showed that patients with BRCA and non-BRCA mutations have similar rates of osteopenia and osteoporosis. This is particularly important for non-BRCA mutation carriers, because there is insufficient data on this subject.

Hereditary breast cancer; Germline pathogenic variants; Osteopenia; Osteoporosis; Bone health

[1] Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, et al; ESMO Guidelines Committee. Bone health in cancer: ESMO clinical practice guidelines. Annals of Oncology. 2020; 31: 1650–1663.

[2] Pandey P, Sharma A, Gogia A. Bone health in breast cancer. Current Problems in Cancer. 2023; 47: 100959.

[3] Khan MI. Management of bone loss due to endocrine therapy during cancer treatment. Osteoporosis International. 2023; 34: 671–680.

[4] Diana A, Carlino F, Giunta EF, Franzese E, Guerrera LP, Di Lauro V, et al. Cancer Treatment-Induced Bone Loss (CTIBL): state of the art and proper management in breast cancer patients on endocrine therapy. Current Treatment Options in Oncology. 2021; 22: 45.

[5] Noel SE, Santos MP, Wright NC. Racial and ethnic disparities in bone health and outcomes in the United States. Journal of Bone and Mineral Research. 2021; 36: 1881–1905.

[6] Tuzun S, Eskiyurt N, Akarirmak U, Saridogan M, Senocak M, Johansson H, et al. Incidence of hip fracture and prevalence of osteoporosis in Turkey: the FRACTURK study. Osteoporosis International. 2012; 23: 949–955.

[7] Gaudio A, Xourafa A, Rapisarda R, Castellino P. Therapeutic options for the management of aromatase inhibitor-associated bone loss. Endocrine, Metabolic & Immune Disorders Drug Targets. 2022; 22: 259–273.

[8] Park S. Health-promoting lifestyle behaviors of Korean American breast cancer survivors. Cancer Nursing. 2023; 46: 252–258.

[9] Bailey S, Lin J. The association of osteoporosis knowledge and beliefs with preventive behaviors in postmenopausal breast cancer survivors. BMC Women’s Health. 2021; 21: 297.

[10] Tuppurainen M, Kroger H, Honkanen R, Puntila E, Huopio J, Saarikoski S, et al. Risks of perimenopausal fractures—a prospective population-based study. Acta Obstet Gynecol Scand. 1995; 74: 624–628.

[11] Shetty S, John B, Mohan S, Paul TV. Vertebral fracture assessment by dual-energy X-ray absorptiometry along with bone mineral density in the evaluation of postmenopausal osteoporosis. Archives of Osteoporosis. 2020; 15: 25.

[12] Comes MC, Arezzo F, Cormio G, Bove S, Calabrese A, Fanizzi A, et al. An explainable machine learning ensemble model to predict the risk of ovarian cancer in BRCA-mutated patients undergoing risk-reducing salpingo-oophorectomy. Frontiers in Oncology. 2023; 13: 1181792.

[13] Ramin C, May BJ, Roden RBS, Orellana MM, Hogan BC, McCullough MS, et al. Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study. Breast Cancer Research. 2018; 20: 134.

[14] do Valle HA, Kaur P, Kwon JS, Cheifetz R, Dawson L, Hanley GE. Bone health after RRBSO among BRCA1/2 mutation carriers: a population-based study. Journal of Gynecologic Oncology. 2022; 33: e51.

[15] Powell CB, Alabaster A, Stoller N, Armstrong MA, Salyer C, Hamilton I, et al. Bone loss in women with BRCA1 and BRCA2 mutations. Gynecologic Oncology. 2018; 148: 535–539.

[16] Chen Z. Fracture risk among breast cancer survivors. Archives of Internal Medicine. 2005; 165: 552.

[17] Kanis JA, Johansson H, McCloskey EV, Liu E, Åkesson KE, Anderson FA, et al. Previous fracture and subsequent fracture risk: a meta-analysis to update FRAX. To be published in Osteoporosis International. 2023. [Preprint]

[18] LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, et al. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporosis International. 2022; 33: 2049–2102.

[19] Malaeb H, El-Khoury JM. Vitamin D and bone fractures revisited. Clinical Chemistry. 2023; 69: 209–209.